Bristol trumpets Opdivo quality-of-life data ahead of Keytruda head and neck cancer showdown

Spotlight

COPENHAGEN, Denmark--Regulatory authorities are already evaluating Bristol-Myers Squibb’s Opdivo in head and neck cancer, based on impressive survival rates posted in a Phase III study. In the meantime, though, Bristol has gone back through through that study data to show its med topped the standards of care in quality-of-life metrics, too.

In the CheckMate-141 study, second-line patients with recurrent or metastatic squamous cell carcinoma of the head and neck reported stabilized symptoms and functioning--including physical and social functioning--during the first 15 weeks of Opdivo treatment, Bristol said Sunday at the ESMO 2016 Congress.

On the flip side, those study participants taking methotrexate, docetaxel or Eli Lilly’s Erbitux saw their quality of life significantly worsen over the same time period.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Opdivo also significantly delayed the worsening of symptoms such as fatigue and insomnia when compared with that trio of treatments.

The data are important, considering the “debilitating physiological effects” that often pile onto the “emotional and social challenges brought on by the condition despite current treatment options,” Kevin Harrington, a professor at the Institute of Cancer Research in London, said in a statement.

And they could also prove useful considering the edge Bristol’s rival, Merck, already has in head and neck cancer with Opdivo archrival Keytruda. That med won the FDA’s green light in August after achieving a 16% response rate in Merck’s Keynote-012 study; 82% of those patients were still responding to the therapy at the 6-month mark.

But BMS may not be that far behind. Regulators are currently weighing its application for a head-and-neck nod, which includes data showing that Opdivo exended the median survival rate of patients to 7.5 months from 5.1 months for the three standards of care. 36% of patients in the study’s Opdivo arm also lived for at least 12 months, results showed.

Related Articles:
Merck's Keytruda wins a double-header with new FDA approval in head-and-neck cancer
Opdivo gives head and neck cancer patients a shot at 12-month survival
Keytruda, Opdivo near new cancer uses where they won't butt heads--at least at first

Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.